title: Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.
abstract: OBJECTIVE
  To evaluate the impact of Ga-68 DOTATOC PET/CT on diagnosis and therapeutic management of patients with multiple endocrine neoplasia (MEN).
  
  
  METHODS
  We did 28 Ga-68 DOTATOC PET/CT in 21 MEN patients (10 female, 11 men; mean age 41.3 years). 109 lesions detected were classified into MEN-associated lesions [i.e., neuroendocrine tumors (NET)] and non-MEN-associated lesions for PET, CT, and PET/CT. The impact of Ga-68 DOTATOC PET/CT on diagnosis and therapeutic management of patients with MEN were assessed by the records of the interdisciplinary NET tumor board including histopathological findings, clinical and radiological follow-up.
  
  
  RESULTS
  Ga-68 DOTATOC PET/CT had an impact on diagnosis and therapeutic management in 10/21 (47.6%) MEN patients. For detecting NET lesions in MEN patients Ga-68 DOTATOC PET/CT reached a sensitivity/specificity of 91.7%/93.5%. There was a significant difference for the detection rate between Ga-68 DOTATOC PET/CT and CT alone (p < 0.001) both using contrast-agent (p = 0.002) or not (p < 0.001) and also a significant difference between contrast-enhanced (CE-) CT and non-CE-CT alone (p = 0.006).
  
  
  CONCLUSIONS
  GA-68 DOTATOC PET/CT allows a high detection rate of NET lesions in the context of MEN-1 syndrome as well as influence therapeutic management in nearly up to half of the patients. GA-68 DOTATOC PET/CT should include a CE-CT to improve MEN-associated NET lesion detection.
authors.affiliation: Department of Radiology, Charité, Universitätsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
authors.forename: Vera
authors.initials: V
authors.lastname: Froeling
authors.forename: Florian
authors.initials: F
authors.lastname: Elgeti
authors.forename: Martin H
authors.initials: MH
authors.lastname: Maurer
authors.forename: Christian
authors.initials: C
authors.lastname: Scheurig-Muenkler
authors.forename: Alexander
authors.initials: A
authors.lastname: Beck
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kroencke
authors.forename: Ulrich-Frank
authors.initials: UF
authors.lastname: Pape
authors.forename: Bernd
authors.initials: B
authors.lastname: Hamm
authors.forename: Winfried
authors.initials: W
authors.lastname: Brenner
authors.forename: Nils F
authors.initials: NF
authors.lastname: Schreiter
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009377:Multiple Endocrine Neoplasia / Q000000981:diagnostic imaging* / Q000628:therapy*; D015282:Octreotide / Q000031:analogs & derivatives*; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D055815:Young Adult
chemical_list: C499142:Ga(III)-DOTATOC; D009942:Organometallic Compounds; D015282:Octreotide